Unraveling the complex genetic model for cystic fibrosis: Pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities

Human Genetics

Volumn 133, Issue 2, 2014, Pages 151-161

  Li, Weili ^a,b   Soave, David ^a,b   Miller, Melissa R ^b   Keenan, Katherine ^b   Lin, Fan ^b   Gong, Jiafen ^b   Chiang, Theodore ^b   Stephenson, Anne L ^c,d   Durie, Peter ^a,b   Rommens, Johanna ^b,d   Sun, Lei ^a   Strug, Lisa J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRYPSINOGEN;

ALLELE; ARTICLE; CANADA; CFTR GENE; CHILD; CYSTIC FIBROSIS; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC MODEL; GENETIC RISK; GENOTYPE; HUMAN; IMMUNOREACTIVITY; INTESTINAL FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MECONIUM ILEUS; MORBIDITY; PANCREAS INJURY; PLEIOTROPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC26A9 GENE; SLC6A14 GENE; SLC9A3 GENE;

ALLELES; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANTIPORTERS; CANADA; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENES, MODIFIER; GENETIC PLEIOTROPY; GENOTYPE; HUMANS; ILEUS; INFANT, NEWBORN; MALE; MECONIUM; MODELS, GENETIC; MORBIDITY; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SODIUM-HYDROGEN ANTIPORTER;

EID: 84893158901     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-013-1363-7     Document Type: Article

References (61)

1. Adler AI, Shine BSF, Chamnan P, Haworth CS, Bilton D (2008) Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care 31:1789-1794. doi: 10.2337/dc08-0466
2. Ahmed N, Corey M, Forstner G, Zielenski J, Tsui L-C, Ellis L, Tullis E, Durie P (2003) Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 52:1159-1164. doi: 10.1136/gut.52.8.1159
3. Anderson CM, Ganapathy V, Thwaites DT (2008) Human solute carrier SLC6A14 is the beta-alanine carrier. J Physiol 586:4061-4067. doi: 10.1113/jphysiol. 2008.154500
4. Avella M, Loriol C, Boulukos K, Borgese F, Ehrenfeld J (2011) SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. J Cell Physiol 226:212-223. doi: 10.1002/jcp.22328
5. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M, Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemkova D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR (2009) for the Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 302:1076-1083. doi: 10.1001/jama.2009.1295
6. Bertrand CA, Zhang R, Pilewski JM, Frizzell RA (2009) SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J Gen Physiol 133:421-438. doi: 10.1085/jgp.200810097
7. Blackman SM, Deering-Brose R, McWilliams R, Naughton K, Coleman B, Lai T, Algire M, Beck S, Hoover-Fong J, Hamosh A, Fallin M, West K, Arking D, Chakravarti A, Cutler D, Cutting G (2006) Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 131:1030-1039
8. Blackman S, Hsu S, Ritter S, Naughton K, Wright F, Drumm M, Knowles M, Cutting G (2009a) A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 52:1858-1865. doi: 10.1007/s00125-009-1436-2
9. Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, Cutting GR (2009b) Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab 94:1302-1309. doi: 10.1210/jc.2008-2186
10. Blackman SM, Commander CW, Watson C, Arcara KM, Strug LJ, Stonebraker JR, Wright FA, Rommens JM, Sun L, Pace RG, Norris SA, Durie PR, Drumm ML, Knowles MR, Cutting GR (2013) Genetic modifiers of cystic fibrosis-related diabetes. Diabetes. doi: 10.2337/db13-0510
11. Bradford EM, Sartor MA, Gawenis LR, Clarke LL, Shull GE (2009) Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. Am J Physiol Gastrointest Liver Physiol 296:G886-G898. doi: 10.1152/ajpgi.90520.2008
12. Chang MH, Plata C, Sindic A, Ranatunga WK, Chen AP, Zandi-Nejad K, Chan KW, Thompson J, Mount DB, Romero MF (2009a) Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domain. J Biol Chem 284:28306-28318. doi: 10.1074/jbc.M109.001669
13. Chang MH, Plata C, Zandi-Nejad K, Sindic A, Sussman CR, Mercado A, Broumand V, Raghuram V, Mount DB, Romero MF (2009b) Slc26a9-anion exchanger, channel and Na+ transporter. J Membr Biol 228:125-140. doi: 10.1007/s00232-009- 9165-5
14. Collaco JM, Morrow CB, Green DM, Cutting GR, Mogayzel PJ (2013) Environmental allergies and respiratory morbidities in cystic fibrosis. Pediatric Pulmonol. doi: 10.1002/ppul.22700
15. Corey M, Edwards L, Levison H, Knowles M (1997) Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 131:809-814
16. Couper RTL, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR (1992) Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res 32:179-182
17. Couper RTL, Corey M, Durie PR, Forstner GG, Moore DJ (1995) Longitudinal evaluation of serum trypsinogen measurement in pancreatic-insufficient and pancreatic-sufficient patients with cystic fibrosis. J Pediatr 127:408-413. doi: 10.1016/S0022-3476(95)70072-2
18. Cystic Fibrosis Canada (2010) Canadian Cystic Fibrosis Patient Data Registry Report. (http://www.cysticfibrosis.ca/assets/files/pdf/cpdr-reporte. pdf). Toronto, Ontario
19. Dorfman R, Taylor C, Lin F, Sun L, Sandford A, Paré P, Berthiaume Y, Corey M, Durie P, Zielenski J, On behalf of the members of the Canadian Consortium for CFGS (2011) Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis. Pediatr Pulmonol 46:385-392. doi: 10.1002/ppul.21372
20. Durie PR, Forstner GG (1999) The exocrine pancreas. In: Cystic fibrosis in adults. Lippincott-Raven Publishers, Philadelphia, pp 261-287
21. Durie PR, Forstner GG, Gaskin KJ, Moore DJ, Cleghorn GJ, Wong SS, Corey ML (1986) Age-related alterations of immunoreactive pancreatic cationic trypsinogen in sera from cystic fibrosis patients with and without pancreatic insufficiency. Pediatr Res 20:209-213
22. Durie PR, Soave D, Gonska T, Ip W, Keenan K, Miller M, Sun L, Rommens J, Strug LJ (2012) Early exocrine pancreatic damage determined by serum immunoreactive trypsinogen is a significant predictor of CF-related diabetes at a later age. North American Cystic Fibrosis Conference, Orlando, Florida. Pediatr Pulmonol 47(S35):408
23. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:91-100. doi: 10.1002/ppul.10127
24. Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, Wright FA, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC, Gibson RL, Bamshad MJ (2012) Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet 44:886-889. doi: 10.1038/ng.2344
25. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wu SC, Klein DJ (1988) Diabetes mellitus associated with cystic fibrosis. J Pediatr 112:373-377
26. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fairley S, Fitzgerald S, Gil L, García- Girón C, Gordon L, Hourlier T, Hunt S, Juettemann T, Kähäri AK, Keenan S, Komorowska M, Kulesha E, Longden I, Maurel T, McLaren WM, Muffato M, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, Riat HS, Ritchie GRS, Ruffier M, Schuster M, Sheppard D, Sobral D, Taylor K, Thormann A, Trevanion S, White S, Wilder SP, Aken BL, Birney E, Cunningham F, Dunham I, Harrow J, Herrero J, Hubbard TJP, Johnson N, Kinsella R, Parker A, Spudich G, Yates A, Zadissa A, Searle SMJ (2013) Ensembl 2013. Nucleic Acids Res 41:D48-D55. doi: 10.1093/nar/gks1236
27. Geokas MC, Largman C, Brodrick JW, Johnson JH (1979) Determination of human pancreatic cationic trypsinogen in serum by radioimmunoassay. Am J Physiol Endocrinol Metab 236:E77-E83
28. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321-327. doi: 10.1038/ng.787
29. Gonska T, Keenan K, Sontag M, Castellani C, Cipolli M, Naehrlich L, Dupuis A, Dorfman R, Taylor C, Sun L, Ooi C, Rommens J, Strug L, Durie P (2012) Meconium ileus prevalence score as new phenotypic marker for the severity of CFTR mutations. North American Cystic Fibrosis Conference, Orlando, Florida. Pediatr Pulmonol 47(S35):386
30. Grasemann H, Ratjen F (2013) Early lung disease in cystic fibrosis. Lancet 1:148-157
31. Johnson J-A, Bush A, Buchdahl R (2010) Does presenting with meconium ileus affect the prognosis of children with cystic fibrosis? Pediatr Pulmonol 45:951-958. doi: 10.1002/ppul.21271
32. Kappler M, Feilcke M, Schröter C, Kraxner A, Griese M (2009) Long-term pulmonary outcome after meconium ileus in cystic fibrosis. Pediatr Pulmonol 44:1201-1206. doi: 10.1002/ppul.21119
33. Kerem B, Rommens J, Buchanan J, Markiewicz D, Cox T, Chakravarti A, Buchwald M, Tsui L (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073-1080. doi: 10.1126/science.2570460
34. Kerem E, Reisman J, Corey M, Canny GJ, Levison H (1992) Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326:1187-1191. doi: 10.1056/NEJM199204303261804
35. Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, McKenzie SG, Navarro J, Strandvik B (2001) Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 32:343-350. doi: 10.1002/ppul.1142
36. Lanng S, Thorsteinsson B, Nerup J, Koch C (1992) Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 151:684-687
37. Li W, Sun L, Corey M, Zou F, Lee S, Cojocaru AL, Taylor C, Blackman SM, Stephenson A, Sandford AJ, Dorfman R, Drumm ML, Cutting GR, Knowles MR, Durie P, Wright FA, Strug LJ (2011) Understanding the population structure of North American patients with cystic fibrosis. Clin Genet 79:136-146. doi: 10.1111/j.1399-0004.2010.01502.x
38. Li M-X, Yeung JY, Cherny S, Sham P (2012) Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. Hum Genet 131:747-756. doi: 10.1007/s00439-011-1118-2
39. Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ (2005) Epidemiology of cystic fibrosis-related diabetes. J Pediatr 146:681-687. doi: 10.1016/j.jpeds.2004.12.039
40. Milla CE, Billings J, Moran A (2005) Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 28:2141-2144. doi: 10.2337/diacare.28.9.2141
41. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W (2009) Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 32:1626-1631. doi: 10.2337/dc09-0586
42. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B (2010) Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 33:2677-2683. doi: 33/12/267710.2337/dc10-1279
43. Munck A, Gérardin M, Alberti C, Ajzenman C, Lebourgeois M, Aigrain Y, Navarro J (2006) Clinical outcome of cystic fibrosis presenting with or without meconium ileus: a matched cohort study. J Pediatr Surg 41:1556-1560. doi: 10.1016/j.jpedsurg.2006.05.014
44. O'Reilly PF, Hoggart CJ, Pomyen Y, Calboli FCF, Elliott P, Jarvelin M-R, Coin LJM (2012) MultiPhen: joint model of multiple phenotypes can increase discovery in GWAS. PLoS ONE 7:e34861. doi: 10.1371/journal.pone.0034861
45. Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, Freedman SD, Zielenski J, Berthiaume Y, Corey M, Schibli S, Tullis E, Durie PR (2011) Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 140:153-161. doi: 10.1053/j.gastro.2010.09.046
46. - conductance in polarized and non-polarized epithelial cells. J Cell Physiol 227:2323-2329. doi: 10.1002/jcp.22967
47. Paaby AB, Rockman MV (2013) The many faces of pleiotropy. Trends Genet TIG 29:66-73
48. R Core Development Team (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
49. Ren CL, Rosenfeld M, Mayer OH, Davis SD, Kloster M, Castile RG, Hiatt PW, Hart M, Johnson R, Jones P, Brumback LC, Kerby GS (2012) Analysis of the associations between lung function and clinical features in preschool children with cystic fibrosis. Pediatr Pulmonol 47:574-581. doi: 10.1002/ppul.21590
50. Rolon MA, Benali K, Munck A, Navarro J, Clement A, Tubiana-Rufi N, Czernichow P, Polak M (2001) Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 90:860-867. doi: 10.1111/j.1651-2227.2001.tb02446.x
51. Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfält R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L (2002) Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 33:483-491. doi: 10.1002/ppul.10100
52. Schluchter MD, Konstan MW, Davis PB (2002) Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 21:1271-1287. doi: 10.1002/sim.1104
53. Sivakumaran S, Agakov F, Theodoratou E, Prendergast James G, Zgaga L, Manolio T, Rudan I, McKeigue P, Wilson James F, Campbell H (2011) Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet 89:607-618. doi: 10.1016/j.ajhg.2011.10.004
54. Sloan JL, Mager S (1999) Cloning and functional expression of a human Na(+) and Cl(-)-dependent neutral and cationic amino acid transporter B(0 +). J Biol Chem 274:23740-23745
55. Solomon MP, Wilson DC, Corey M, Kalnins D, Zielenski J, Tsui LC, Pencharz P, Durie P, Sweezey NB (2003) Glucose intolerance in children with cystic fibrosis. J Pediatr 142:128-132. doi: S0022-3476(02)40207-710.1067/mpd.2003.5
56. Sontag MK, Corey M, Hokanson JE, Marshall JA, Sommer SS, Zerbe GO, Accurso FJ (2006) Genetic and physiologic correlates of longitudinal immunoreactive trypsinogen decline in infants with cystic fibrosis identified through newborn screening. J Pediatr 149(650-657):e2
57. Sun L, Rommens JM, Corvol H, Li W, Li X, Chiang TA, Lin F, Dorfman R, Busson PF, Parekh RV, Zelenika D, Blackman SM, Corey M, Doshi VK, Henderson L, Naughton KM, O'Neal WK, Pace RG, Stonebraker JR, Wood SD, Wright FA, Zielenski J, Clement A, Drumm ML, Boelle PY, Cutting GR, Knowles MR, Durie PR, Strug LJ (2012) Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 44:562-569. doi: 10.1038/ng.2221
58. Taylor C, Commander CW, Collaco JM, Strug LJ, Li W, Wright FA, Webel AD, Pace RG, Stonebraker JR, Naughton K, Dorfman R, Sandford A, Blackman SM, Berthiaume Y, Paré P, Drumm ML, Zielenski J, Durie P, Cutting GR, Knowles MR, Corey M (2011) A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis Genetic modifier studies. Pediatr Pulmonol 46:857-869. doi: 10.1002/ppul.21456
59. Vanscoy LL, Blackman SM, Collaco JM, Bowers A, Lai T, Naughton K, Algire M, McWilliams R, Beck S, Hoover-Fong J, Hamosh A, Cutler D, Cutting GR (2007) Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 175:1036-1043. doi: 10.1164/rccm.200608-1164OC
60. Wilcken B (2009) Cystic fibrosis: refining the approach to newborn screening. J Pediatr 155:605-606. doi: 10.1016/j.jpeds.2009.05.015
61. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM, Corey M, Dorfman R, Goddard K, Green D, Kent JW, Lange EM, Lee S, Li W, Luo J, Mayhew GM, Naughton KM, Pace RG, Pare P, Rommens JM, Sandford A, Stonebraker JR, Sun W, Taylor C, Vanscoy LL, Zou F, Blangero J, Zielenski J, O'Neal WK, Drumm ML, Durie PR, Knowles MR, Cutting GR (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43:539-546. doi: 10.1038/ng.838